1. AB0281 SAFETY AND RETENTION RATE AFTER SWITCHING FROM ETANERCEPT ORIGINATOR (ETN) TO ETANERCEPT BIOSIMILAR (SB4) IN INFLAMMATORY JOINT DISEASES: DATA FROM REAL LIFE. (2nd June 2020) Authors: Bruni, C.; Gentileschi, S.; Capassoni, M.; Pacini, G.; Bardelli, M.; Baldi, C.; Tofani, L.; Cometi, L.; Nacci, F.; Bartoli, F.; Fiori, G.; Cantarini, L.; Guiducci, S.; Frediani, B.; Matucci-Cerinic, M. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0374 LUPUS LOW DISEASE ACTIVITY STATE AND MAINTAINING DRUG THERAPY: A RETROSPECTIVE INVESTIGATION. (2nd June 2020) Authors: Gotelli, E.; Sulli, A.; Ferrari, G.; Pacini, G.; Schenone, C.; Patanè, M.; Bica, P. F.; Pizzorni, C.; Cutolo, M.; Paolino, S. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0408 DOES THE PRESENCE IN THE SERUM OF ANTIPHOSPHOLIPID ANTIBODIES CORRELATE WITH SPECIFIC/NON SPECIFIC CAPILLAROSCOPIC ABNORMALITIES?. (2nd June 2020) Authors: Ferrari, G.; Paolino, S.; Sulli, A.; Pizzorni, C.; Pacini, G.; Gotelli, E.; Lercara, A.; Smith, V.; Cutolo, M. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1504 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB1012 Bone mass changes correlate with disease activity in non-arthropathic psoriatic patients. (12th June 2018) Authors: Paolino, S.; Gotelli, E.; Pacini, G.; Alessandri, E.; Casabella, A.; Ghio, M.; Cattelan, F.; Goegan, F.; Patané, M.; Cutolo, M. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Circulating adiponectin concentration is inversely associated with glucose tolerance and insulin secretion in people with newly diagnosed diabetes. Issue 2 (17th November 2016) Authors: Weber, K. S.; Strassburger, K.; Pacini, G.; Nowotny, B.; Müssig, K.; Szendroedi, J.; Herder, C.; Roden, M. Journal: Diabetic medicine Issue: Volume 34:Issue 2(2017) Page Start: 239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and Safety of Vildagliptin in New‐Onset Diabetes After Kidney Transplantation—A Randomized, Double‐Blind, Placebo‐Controlled Trial. Issue 1 (26th November 2013) Authors: Haidinger, M.; Werzowa, J.; Hecking, M.; Antlanger, M.; Stemer, G.; Pleiner, J.; Kopecky, C.; Kovarik, J. J.; Döller, D.; Pacini, G.; Säemann, M. D. Journal: American journal of transplantation Issue: Volume 14:Issue 1(2014:Jan.) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas–kidney transplantation with systemic venous insulin delivery. (11th May 2013) Authors: Stadler, M.; Krššák, M.; Jankovic, D.; Göbl, C.; Winhofer, Y.; Pacini, G.; Bischof, M.; Haidinger, M.; Saemann, M.; Mühlbacher, F.; Korbonits, M.; Baumgartner‐Parzer, S. M.; Luger, A.; Prager, R.; Anderwald, C.‐H.; Krebs, M. Journal: Clinical endocrinology Issue: Volume 80:Number 2(2014:Feb.) Page Start: 208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Glucose‐lowering effect of the DPP‐4 inhibitor sitagliptin after glucose and non‐glucose macronutrient ingestion in non‐diabetic subjects. Issue 6 (7th February 2013) Authors: Ohlsson, L.; Alsalim, W.; Carr, R. D.; Tura, A.; Pacini, G.; Mari, A.; Ahrén, B. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 6(2013:Jun.) Page Start: 531 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes. Issue 6 (25th March 2015) Authors: Pacini, G.; Mari, A.; Fouqueray, P.; Bolze, S.; Roden, M. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 6(2015:Jun.) Page Start: 541 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes. Issue 6 (25th March 2015) Authors: Pacini, G.; Mari, A.; Fouqueray, P.; Bolze, S.; Roden, M. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 6(2015:Jun.) Page Start: 541 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗